Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron ...

So while biosimilars have caused some price erosion ... acts as a “reverse DCF,” as it reveals what market assumptions are implied by Regeneron’s valuation. This implies that my base ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Regeneron (REGN) to Overweight from Neutral with a price target of ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

TD Cowen also adjusted its price target for Regeneron to $1,030, lowering revenue estimates for the Eylea franchise due to increased market competition. Leerink Partners reduced its price target ...

Regeneron Pharmaceuticals has a 1 year low of $615.00 and a 1 year high of $1,211.20. The company has a market capitalization of $67.45 billion, a PE ratio of 16.12, a price-to-earnings-growth ...

Market Capitalization: $74.87 Billion Regeneron Pharmaceuticals ... The analyst kept his price target of $1,152 while noting ...

The overall negative market sentiment contributed to Regeneron's price movement, emphasizing the impact of macroeconomic factors. Buy, Hold or Sell Regeneron Pharmaceuticals? View our complete ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 4.06% to $634.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 2.39% to $610.64 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 4. ...